Terms: = Brain cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Prognosis
12 results:
1. Single-cell RNA sequencing of anaplastic ependymoma and H3K27M-mutant diffuse midline glioma.
Zang D; Dong Z; Liu Y; Chen Q
BMC Neurol; 2024 Feb; 24(1):74. PubMed ID: 38383423
[TBL] [Abstract] [Full Text] [Related]
2. Multi-omics analyses of choroid plexus carcinoma cell lines reveal potential targetable pathways and alterations.
Hesham D; On J; Alshahaby N; Amer N; Magdeldin S; Okada M; Tsukamoto Y; Hiraishi T; Imai C; Okuda S; Wakai T; Kakita A; Oishi M; El-Naggar S; Natsumeda M
J Neurooncol; 2024 Jan; 166(1):27-38. PubMed ID: 38190092
[TBL] [Abstract] [Full Text] [Related]
3. The expression and prognostic value of the epidermal growth factor receptor family in glioma.
Xu B; Huo Z; Huang H; Ji W; Bian Z; Jiao J; Sun J; Shao J
BMC Cancer; 2021 Apr; 21(1):451. PubMed ID: 33892666
[TBL] [Abstract] [Full Text] [Related]
4. Neratinib in the early-stage/extended adjuvant breast cancer patient.
O'Shaughnessy JA; Isaacs C; O'Regan R
Clin Adv Hematol Oncol; 2020 Aug; 18 Suppl 12(8):1-20. PubMed ID: 33843843
[TBL] [Abstract] [Full Text] [Related]
5. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract] [Full Text] [Related]
6. A pan-HER-targeted approach for recurrent or late-stage cervical cancer therapy: mechanisms, recent advances, and clinical prospects.
Liu Y; An Q; Zhao X
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4123-4131. PubMed ID: 32373948
[TBL] [Abstract] [Full Text] [Related]
7. Circular RNA circ_0074026 indicates unfavorable prognosis for patients with glioma and facilitates oncogenesis of tumor cells by targeting miR-1304 to modulate erbb4 expression.
Chen M; Liu X; Xie P; Wang P; Liu M; Zhan Y; Wang H; Feng Y; Li Y
J Cell Physiol; 2020 May; 235(5):4688-4697. PubMed ID: 31643077
[TBL] [Abstract] [Full Text] [Related]
8. A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk.
Andersson U; Schwartzbaum J; Wiklund F; Sjöström S; Liu Y; Tsavachidis S; Ahlbom A; Auvinen A; Collatz-Laier H; Feychting M; Johansen C; Kiuru A; Lönn S; Schoemaker MJ; Swerdlow AJ; Henriksson R; Bondy M; Melin B
Acta Oncol; 2010 Aug; 49(6):767-75. PubMed ID: 20446891
[TBL] [Abstract] [Full Text] [Related]
9. Systems-level analysis of erbb4 signaling in breast cancer: a laboratory to clinical perspective.
Chuu CP; Chen RY; Barkinge JL; Ciaccio MF; Jones RB
Mol Cancer Res; 2008 Jun; 6(6):885-91. PubMed ID: 18567793
[TBL] [Abstract] [Full Text] [Related]
10. prognosis-related histomorphological and immunohistochemical markers in central nervous system tumors of childhood and adolescence.
Rickert CH; Paulus W
Acta Neuropathol; 2005 Jan; 109(1):69-92. PubMed ID: 15647946
[TBL] [Abstract] [Full Text] [Related]
11. prognosis-related molecular markers in pediatric central nervous system tumors.
Rickert CH
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1211-24. PubMed ID: 15624758
[TBL] [Abstract] [Full Text] [Related]
12. CI-1033, a pan-erbB tyrosine kinase inhibitor.
Slichenmyer WJ; Elliott WL; Fry DW
Semin Oncol; 2001 Oct; 28(5 Suppl 16):80-5. PubMed ID: 11706399
[TBL] [Abstract] [Full Text] [Related]
